{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-281980","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.239120+00:00","generated_at":"2026-06-21T23:31:50.622133+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Benitec Q1 net loss $5.1M, cash $16.5M; OPMD NH study screening starts Nov 2022","bullets":["Net loss of $5.1M ($0.47 loss per share) for fiscal Q1 ended Sep 30, 2022.","Cash and cash equivalents of $16.5M as of Sep 30, 2022, up from $4.1M at Jun 30.","OPMD Natural History Study IRB approval received; subject screening begins Nov 2022 at US lead site.","BB-301 Phase 1b/2a IND/CTA filings planned for Q1 2023; first dosing expected Q2 2023.","R&D expenses $2.7M, G&A $1.9M for the quarter, both slightly down year-over-year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-281980","json":"https://secwatch.observer/filing/0001193125-22-281980.json","markdown":"https://secwatch.observer/filing/0001193125-22-281980.md","text":"https://secwatch.observer/filing/0001193125-22-281980.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312522281980/0001193125-22-281980-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312522281980/d412509d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:31:50.622133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a4477d316310f4e73427c7d0a58e84a5aa85468","claim":"Benitec Biopharma Inc. reported financial results for its fiscal quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022 Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312522281980/0001193125-22-281980-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"its fiscal quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}